VYNE Therapeutics Inc. (VYNE)
NASDAQ$1.87
Market Cap
$28.44M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
342 of 924
Rank in Industry
201 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
VYNE Insider Trading Activity
VYNE Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $43,800 | 1 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| LEPORE PATRICK G | director | 1 | $43,800 | 0 | $0 | $43,800 |
About VYNE Therapeutics Inc.
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various …
Insider Activity of VYNE Therapeutics Inc.
Over the last 12 months, insiders at VYNE Therapeutics Inc. have bought $43,800 and sold $0 worth of VYNE Therapeutics Inc. stock.
On average, over the past 5 years, insiders at VYNE Therapeutics Inc. have bought $5.19M and sold $5.32M worth of stock each year.
Highest buying activity among insiders over the last 12 months: LEPORE PATRICK G (director) — $43,800.
The last purchase of 15,000 shares for transaction amount of $43,800 was made by LEPORE PATRICK G (director) on 2025‑01‑15.
List of Insider Buy and Sell Transactions, VYNE Therapeutics Inc.
| 2025-01-15 | LEPORE PATRICK G | director | 15,000 0.106% | $2.92 | $43,800 | -11.59% | ||
| 2023-11-15 | LEPORE PATRICK G | director | 13,000 0.3748% | $3.91 | $50,778 | -45.75% | ||
| 2021-11-30 | LEPORE PATRICK G | director | 12,500 0.024% | $1.02 | $12,699 | -55.58% | ||
| 2021-08-25 | LEPORE PATRICK G | director | 12,500 0.0243% | $1.60 | $20,000 | -62.27% | ||
| 2021-08-16 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 250,000 0.4697% | $1.74 | $435,000 | -64.78% | |
| 2021-08-13 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 250,000 0.4967% | $1.84 | $460,000 | -64.61% | |
| 2021-08-12 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 338,897 0.7299% | $2.23 | $755,740 | -68.34% | |
| 2021-05-26 | LEPORE PATRICK G | director | 12,500 0.0241% | $3.60 | $44,958 | -68.32% | ||
| 2021-05-06 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 1M 2.0052% | $3.67 | $3.67M | -65.17% | |
| 2021-03-15 | LEPORE PATRICK G | director | 12,500 0.0259% | $7.41 | $92,563 | -79.34% | ||
| 2021-01-28 | PERCEPTIVE ADVISORS LLC | 10 percent owner | 4.22M 2.2941% | $2.37 | $10M | -69.62% | ||
| 2020-12-03 | LEPORE PATRICK G | director | 100,000 0.078% | $1.71 | $170,850 | -46.15% | ||
| 2020-09-08 | Domzalski David | President and CEO | 150,000 0.084% | $1.38 | $207,135 | +10.54% | ||
| 2020-09-08 | Saik Andrew | Chief Financial Officer | 80,000 0.0474% | $1.46 | $116,960 | +10.54% | ||
| 2020-06-09 | PERCEPTIVE ADVISORS LLC | 10 percent owner | 5.41M 3.4508% | $1.85 | $10M | -19.14% | ||
| 2018-07-24 | Sale | Presidio Partners 2007 GP, L.P. | 1M 4.3407% | $7.65 | $7.65M | -11.34% | ||
| 2018-01-25 | Remeditex Ventures LLC | 10 percent owner | 200,000 0.6735% | $17.00 | $3.4M | -71.72% | ||
| 2018-01-25 | venBio Global Strategic Fund II L.P. | 10 percent owner | 530,000 1.7848% | $17.00 | $9.01M | -71.72% | ||
| 2018-01-25 | Vivo Capital VIII, LLC | 10 percent owner | 588,236 1.9809% | $17.00 | $10M | -71.72% | ||
| 2018-01-25 | Cha Albert | director | 588,236 1.9809% | $17.00 | $10M | -71.72% |
Total: 20
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| LEPORE PATRICK G | director | 51472 0.3384% | $96,252.64 | 7 | 0 | <0.0001% |
| PERCEPTIVE ADVISORS LLC | 10 percent owner | 4935057 32.4463% | $9.23M | 2 | 4 | <0.0001% |
| Remeditex Ventures LLC | 10 percent owner | 1582854 10.4067% | $2.96M | 1 | 0 | |
| Domzalski David | President and CEO | 1315966 8.652% | $2.46M | 1 | 0 | +10.54% |
| Saik Andrew | Chief Financial Officer | 340000 2.2354% | $635,800.00 | 1 | 0 | +10.54% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$14,315,062 | 61 | -6.21% | $33.06M | |
$53,490,060 | 55 | 19.35% | $30.29M | |
$94,084,626 | 29 | -21.08% | $24.05M | |
$1,295,471 | 17 | 21.79% | $25.73M | |
$17,594,514 | 16 | -20.37% | $33.77M |
VYNE Institutional Investors: Active Positions
| Increased Positions | 19 | +55.88% | 1M | +14.41% |
| Decreased Positions | 12 | -35.29% | 646,991 | -8.8% |
| New Positions | 9 | New | 939,171 | New |
| Sold Out Positions | 6 | Sold Out | 514,615 | Sold Out |
| Total Postitions | 41 | +20.59% | 8M | +5.61% |
VYNE Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Cormorant Asset Management, Lp | $2,580.00 | 9.3% | 1.39M | 0 | 0% | 2024-12-31 |
| Eventide Asset Management, Llc | $2,580.00 | 9.3% | 1.39M | 0 | 0% | 2024-12-31 |
| Citadel Advisors Llc | $2,276.00 | 8.2% | 1.23M | +43,044 | +3.63% | 2024-12-31 |
| Dsc Advisors, L.P. | $1,288.00 | 4.64% | 696,465 | 0 | 0% | 2024-09-30 |
| Vanguard Group Inc | $879.00 | 3.17% | 475,129 | +31,611 | +7.13% | 2024-12-31 |
| Acorn Capital Advisors, Llc | $845.00 | 3.05% | 456,970 | +456,970 | New | 2024-12-31 |
| Palo Alto Investors Lp | $824.00 | 2.97% | 445,434 | 0 | 0% | 2024-12-31 |
| Exome Asset Management Llc | $654.00 | 2.36% | 353,434 | 0 | 0% | 2024-12-31 |
| Oconnor, A Distinct Business Unit Of Ubs Asset Management Am | $455.00 | 1.64% | 245,800 | +245,800 | New | 2024-12-31 |
| Schonfeld Strategic Advisors Llc | $327.00 | 1.18% | 176,658 | +8,058 | +4.78% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.